Table 4.
Proportion of ever-employed adults with current asthma by asthma treatment groupa and WRA status.
| Treatment groupb | WRA (N =2 224 263)c %c (95% CI) |
Possible WRA (N =6 094 064)c %c (95% CI) |
Non-WRA (N = 6 784 072)c %c (95% CI) |
WRA vs non-WRA PRd (95% CI) |
Possible WRA vs non-WRA PRd (95% CI) |
|---|---|---|---|---|---|
| Short-acting β-agonist (SABA) | 35.8 (30.3–41.3) | 38.3 (35.0–41.7) | 38.3 (34.5–42.0) | 0.90 (0.75–1.08) | 0.91 (0.81–1.04) |
| Inhaled corticosteroid (ICS) + SABA | 12.3 (7.4–17.1) | 15.9 (12.9–18.8) | 16.1 (13.5–18.8) | 0.74 (0.47–1.17) | 0.99 (0.77–1.28) |
| Cromolyn/nedocromil, leukotriene receptor agonist (LTRA), or theophylline + SABA | 8.6 (5.8–11.3) | 7.1 (5.3–8.8) | 9.0 (6.7–11.3) | 1.11 (0.74–1.66) | 1.03 (0.72–1.46) |
| ICS + long-acting β-agonist (LABA) + SABA | 24.0 (19.8–28.1) | 26.1 (23.2–29.1) | 26.1 (23.2–29.0) | 0.90 (0.72–1.12) | 1.01 (0.86–1.18) |
| ICS + LTRA, theophylline, or zileuton + SABA | 16.2 (12.1–20.2) | 10.2 (8.6–11.8) | 8.2 (6.6–9.9) | 2.21 (1.57–3.11) | 1.41 (1.05–1.89) |
| ICS + LABA + oral corticosteroid + SABA | 2.8 (1.7–3.9) | 1.2 (0.7–1.7) | 2.0 (1.0–3.1) | 1.34 (0.78–2.30) | 0.68 (0.39–1.19) |
a
In 3 months preceding the Asthma Call-back Survey interview.
b
Treatment groups based on NAEPP Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma.
c
Results presented as weighted annual average.
d
Consists of model where the outcome variable was the treatment group and the predictor variable was the WRA status, adjusted for age, sex, race/ethnicity, income, health insurance, current employment status, chronic obstructive pulmonary disease, and adverse asthma outcomes.
CI, confidence interval; PR, prevalence ratio; WRA, work-related asthma; Bold text indicates significance.